factual
Rapamycin evidence stronger than metformin
The case for metformin as a geroprotective is weaker than a decade ago—a 2014 study suggesting mortality benefit had methodological problems and a corrected repeat found the opposite, suggesting metformin is at best mildly geroprotective only in diabetics—whereas rapamycin succeeds repeatedly in the NIH Interventions Testing Program where metformin fails, though human data remain lacking.
factualpending
Speaker
Peter AttiaEvidence Quote
“i think the data for rapamycin are significantly better than the data for metformin but we are sufficiently lacking in human data for rapamycin”
Created: 6/14/2026, 2:19:52 AM
Your notes
Loading notes...